Bellicum Pharmaceuticals Analysis

BLCMDelisted Stock  USD 0.37  0.05  11.90%   
Bellicum Pharmaceuticals is overvalued with Real Value of 0.35 and Hype Value of 0.37. The main objective of Bellicum Pharmaceuticals pink sheet analysis is to determine its intrinsic value, which is an estimate of what Bellicum Pharmaceuticals is worth, separate from its market price. There are two main types of Bellicum Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Bellicum Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Bellicum Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Bellicum Pharmaceuticals pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Bellicum Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Bellicum Pink Sheet trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Bellicum Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

Bellicum Pink Sheet Analysis Notes

About 29.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.0. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bellicum Pharmaceuticals recorded a loss per share of 1.57. The entity last dividend was issued on the 6th of February 2020. The firm had 1:10 split on the 6th of February 2020. Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas. Bellicum Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.The quote for Bellicum Pharmaceuticals is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Bellicum Pharmaceuticals please contact Richard Fair at 281 454 3424 or go to https://www.bellicum.com.

Bellicum Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more pink sheets at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bellicum Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bellicum Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bellicum Pharmaceuticals is not yet fully synchronised with the market data
Bellicum Pharmaceuticals has some characteristics of a very speculative penny stock
Bellicum Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 1.5 M. Net Loss for the year was (24.97 M) with loss before overhead, payroll, taxes, and interest of (17.38 M).
Bellicum Pharmaceuticals currently holds about 33.17 M in cash with (25.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Bellicum Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Bellicum Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bellicum Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
10th of August 2023
Upcoming Quarterly Report
View
9th of November 2023
Next Financial Report
View
30th of June 2023
Next Fiscal Quarter End
View
31st of March 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Bellicum Pharmaceuticals Thematic Classifications

In addition to having Bellicum Pharmaceuticals pink sheet in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters Idea
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

Bellicum Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bellicum Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Bellicum Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Bellicum Pharmaceuticals Predictive Daily Indicators

Bellicum Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bellicum Pharmaceuticals pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

About Bellicum Pink Sheet Analysis

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Bellicum Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bellicum shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Bellicum Pharmaceuticals. By using and applying Bellicum Pink Sheet analysis, traders can create a robust methodology for identifying Bellicum entry and exit points for their positions.
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas. Bellicum Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Bellicum Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Volatility Now

   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Module
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Bellicum Pharmaceuticals information on this page should be used as a complementary analysis to other Bellicum Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Consideration for investing in Bellicum Pink Sheet

If you are still planning to invest in Bellicum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellicum Pharmaceuticals' history and understand the potential risks before investing.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance